Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in patients on stable dialysis (Alidial)
NCT03480568Phase 3Unknown
- Sponsor
- Baylor Scott & White Research Institute
- Start
- May 2018
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 3, open-label trial of alirocumab in hypercholesterolemia, sponsored by Baylor Scott & White Research Institute. Primary endpoint: Low-Density Lipoprotein cholesterol at 12 weeks. Status: unknown.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03480568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480568.